Skip to main content
TipRanks
Go Ultimate75% OFF

S&S Healthcare Holding Ltd. (4198) AI Stock Analysis

TW:4198

S&S Healthcare Holding Ltd.

(TPEx:4198)

Select Model
Rating:40Underperform
Price Target:TWD 42.00â–¼(-12.50% Downside)
Action:initiatedcoverage
Date:11/10/26

The score is constrained primarily by persistent operating losses, declining revenue, and negative cash flow. Reduced leverage and substantial equity provide financial support, but weak technical momentum and loss-based valuation keep the overall score near the bottom of the range.

Positive Factors
De-risked Balance SheetSharply lower leverage and substantial equity relative to assets provide a stronger financial foundation than in 2020–2022. This de-risking can improve resilience and preserve room to support operations, even though losses continue to pressure returns.
Negative Factors
Persistent Operating LossesNegative EBIT and net income in 2024–2025 show that increased revenue has not yet translated into sustainable earnings. Persistent losses weaken earnings visibility, reduce internally generated capital, and make the business more dependent on successful execution before it can support durable returns.

S&S Healthcare Holding Ltd. (4198) vs. SPDR S&P 500 ETF (SPY)

-20%-10%0%10%20%30%40%TW:4198+26.32%SPY+14.30%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 1.08B
Dividend Yield
―
Average Volume (3M)
7,926
Price to Earnings (P/E)
-28.1
Beta (1Y)
0.30
Revenue Growth
―
EPS Growth
―
Country
TW
Employees
200
Sector
General
Sector Strength
55
Industry
Medical - Devices

S&S Healthcare Holding Ltd. Business Overview & Revenue Model

Company Description

S&S Healthcare Holding Ltd. is dedicated to the research, manufacturing, and global commercialization of medical imaging equipment. The company's operations extend across international markets, including significant presences in Taiwan, the United St...

S&S Healthcare Holding Ltd. Financial Statement Overview

Summary

Financial performance is weak overall: the income statement score is 18 due to declining revenue and widening losses, and the cash flow score is 25 because operating and free cash flow remain negative. The balance sheet score of 68 provides support through materially lower debt and improved leverage.

Income Statement

18Very Negative

Balance Sheet

68Positive

Cash Flow

25Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue171.88M204.21M240.25M275.11M254.44M122.35M
Gross Profit53.22M58.85M75.01M35.66M38.39M-7.93M
EBITDA-28.59M-27.02M-17.60M133.81M-33.61M-71.64M
Net Income-40.47M-47.30M-41.28M103.61M-66.89M-95.39M
Balance Sheet
Total Assets353.99M377.06M433.83M613.34M531.06M294.12M
Cash, Cash Equivalents and Short-Term Investments73.47M122.39M150.02M198.99M112.32M121.88M
Total Debt25.38M28.44M53.32M88.08M183.91M124.06M
Total Liabilities101.62M100.37M116.24M209.24M315.64M199.92M
Stockholders Equity204.00M226.50M260.85M300.74M135.25M54.99M
Cash Flow
Free Cash Flow-39.80M-29.12M-71.10M-99.25M-142.07M-80.36M
Operating Cash Flow-34.83M-26.66M-52.04M-68.10M-72.91M-70.52M
Investing Cash Flow15.62M12.33M7.22M181.95M-82.25M-9.25M
Financing Cash Flow-14.14M-33.66M-4.56M-29.59M149.97M112.47M

S&S Healthcare Holding Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TW:4198 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TW:6242TW:624261NeutralTWD 1.07B13.90―5.97%-0.93%-10.65%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TW:4109TW:410945NeutralTWD 1.21B256.25―1.95%13.00%902.22%
TW:4121TW:412142NeutralTWD 1.01B-25.02――0.08%-10.61%
TW:4198TW:419840UnderperformTWD 1.10B-28.07――――

* General Sector Average

Performance Comparison

0%50%100%TW:4198TW:4109TW:4121TW:6242TW:6518TW:6543Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:4198 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:4198S&S Healthcare Holding Ltd.48.0010.0026.32%
TW:4109Jia Jie Biomedical Co., Ltd.10.25-5.51-34.96%
TW:4121Rossmax International Ltd.12.25-3.05-19.93%
TW:6242LI KANG BIOMEDICAL Co. Ltd.33.50-3.36-9.12%
TW:6518Concord Medical Co Ltd29.854.9820.00%
TW:6543Perfect Medical Industry Co., Ltd.16.55-10.96-39.85%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026